Allergic Rhinitis Drugs Market Analysis

Allergic Rhinitis Drugs Market Analysis

To get key market trends

  Download Free Sample

Based on disease, the industry is split into seasonal allergic rhinitis, occupational allergic rhinitis, and perennial allergic rhinitis. The seasonal allergic rhinitis segment accounted for more than 42% of the allergic rhinitis drugs market share in 2022 and is further slated to witness robust growth in the coming years. The rise in breathing-related illnesses caused by outdoor allergens including weed and grass pollen is proliferating product uptake. As per the Asthma and Allergy Foundation of America, grass pollen affects around 10 to 30% of children and adults in the United States.
 

The allergic rhinitis drugs market is categorized in terms of drug into prescription and OTC. The prescription segment is speculated to account for a valuation of over USD 8.5 billion by 2032. The strong inclination of allergic patients experiencing a runny nose, itchy eyes, postnasal drip, and other symptoms toward prescription drugs is primarily accelerating segment share. The segment growth is also driven by the inclusion of a wide range of allergic drugs from several categories, including corticosteroids, antihistamines, and leukotriene receptor antagonists, among others, under the prescribed drug segment.
 

With respect to treatment, the allergic rhinitis drugs market is divided into antihistamines, corticosteroids, immunotherapy, decongestants, and others. The immunotherapy segment is poised to depict over 3% CAGR from 2023 to 2032. By using this technique, the body's immune system builds up an immunity to tolerate allergens and doesn't react to active allergens. As a result of its effectiveness on SAR patients, immunotherapy is considered the only disease-modifying therapy for allergic rhinitis. In addition, providers increase allergens in every shot, escalating immunity in the body.
 

Based on the route of administration, the industry is classified into oral, intraocular, nasal, and intravenous. The allergic rhinitis drugs market size from the oral segment is anticipated to garner more than USD 6.5 billion in revenue by 2032. The clinical advantages associated with the oral route of administration, such as its high level of convenience, low cost, and non-invasive approach, are encouraging segment uptake. Tablets, capsules, and solutions, among other formulations, are used to administer the oral dose.
 

In terms of distribution channel, the allergic rhinitis drugs market is separated into hospital pharmacies, retail pharmacies, and online channel. The online channel segment valuation is foreseen to reach over USD 4 billion by 2032. The rising use of online portals and e-commerce platforms for ordering and delivering prescription drugs at the convenience of patients is set to foster segment growth. Moreover, the availability of swift service, beneficial discounts & offers from various manufacturers, and the strong preference of elderly patients are driving the segment growth.
 

In the regional context, the allergic rhinitis drugs market is segmented into Europe, Asia Pacific, North America, the Middle East & Africa, and Latin America. The North America market registered more than 37% revenue share in 2022. Soaring technological developments in treatment methods such as corticosteroid drugs are fueling business outlook. For instance, in March 2022, US FDA approved Rx-to-OTC for Nasonex by Perrigo. Moreover, the positive focus of industry players on OTC product portfolio and rising healthcare expenditures are accelerating regional market expansion.